BiotechTube

Placebo

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Leber Hereditary Optic Neuropathy

Conditions

Leber Hereditary Optic Neuropathy

Trial Timeline

Mar 12, 2018 → Jul 23, 2024

NCT ID
NCT03293524

About Placebo

Placebo is a phase 3 stage product being developed by GenSight Biologics for Leber Hereditary Optic Neuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT03293524. Target conditions include Leber Hereditary Optic Neuropathy.

What happened to similar drugs?

1 of 4 similar drugs in Leber Hereditary Optic Neuropathy were approved

Approved (1) Terminated (1) Active (2)
✅IdebenoneSanthera PharmaceuticalsApproved
❌Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
🔄GS010GenSight BiologicsPhase 3
🔄GS010GenSight BiologicsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03293524Phase 3Completed

Competing Products

12 competing products in Leber Hereditary Optic Neuropathy

See all competitors
ProductCompanyStageHype Score
EDIT-101Editas MedicinePhase 1/2
18
AAV RPE65MeiraGTxPhase 1/2
26
AAV OPTIRPE65MeiraGTxPre-clinical
20
Idebenone + PlaceboSanthera PharmaceuticalsPhase 2
25
IdebenoneSanthera PharmaceuticalsApproved
33
Idebenone 150 MG Oral TabletSanthera PharmaceuticalsPre-clinical
16
IdebenoneSanthera PharmaceuticalsPre-clinical
16
sepofarsenProQRPhase 2/3
24
sepofarsenProQRPhase 2/3
32
Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
22
GS010GenSight BiologicsPhase 3
30
GS010GenSight BiologicsPhase 3
30